53

PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

Page 1: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*
Page 2: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

1

e. prof. p. dr. Romualdas

doc. dr. Audra

doc. dr. Jurgis BOJARSKAS

dr. Audrius

habil. dr. Robertas

prof. habil. dr. Vida Marija

doc. dr. Remigijus

dr. Virgilijus

doc. dr. Sabina , Lundo universitetas, Švedija

doc. dr. Aleksandras KIBARSKIS

prof. habil. dr. Limas

doc. habil. dr. Alvydas

prof. habil. dr. Vanda

prof. habil. dr. Antanas

prof. habil. dr. Alvydas

prof. habil. dr. Juozas

doc. dr. Raimondas

doc. dr. Vytautas

prof. Arvydas

prof. habil. dr. Povilas ,

prof. habil. dr. Remigijus

dr. Regina

(8*698) 4 43 13

(8*610) 0 73 05

(8*37) 33 10 09

Maketuotoja Asta

El. paštas: [email protected] internete: http://www.medicine.ltRedakcijos tel.: prenumerata (8*37) 33 09 77, (8*5) 237 52 14

reklama (8*37) 33 10 09, (8*37) 33 15 59faksas (8*37) 33 15 34

Vilniaus biuro tel. (8*5) 237 52 14

A............................................................. 2

........................................................... 4

A............................................................... 6

................... 8..................................................... 10

A....... 13

............ 15

antipsichozinis vaistas........................................................................... 17Escitalopramo (Cipralex) farmakodinaminio poveikio ypatumai ......... 21Atipiniai antipsichoziniai vaistai. Kokie jie?............................................ 24

.................................................................... 27

................................................................................... 30

I............... 32

.................................................. 34......................................... 35

prie šio ryšio sampratos ........................................................................ 37........ 39

................................................................................... 40

S............. 42

............................................................................. 44

A............................................................................ 46

Psichoterapija gerontopsichiatrijoje .......................................................... 47Psichoterapija internetu .............................................................................. 49

.......................................... 51Atviras laiškas .............................................................................................. 52

I............................................................... 53

........................ 43, 48, 51, 54

SKELBIMAI............................................................................................. 55

Page 3: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

2

-

--

--

---

-

-

--

--

-

--

---

-

-

-

-

--

-

Globalizacijos procesas ir depresija

Page 4: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

3

-

--

-

-

--

-

-

-

--

-

--

-

-

-

-

-

-

--

--

-

-

-

-

Medicinos centras „Neuromeda“ ___________________________________________________________________________

Page 5: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

4

-

-

-

-

--

--

-

-

--

-

---

-

-

Nuotr.

Page 6: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

5

-

-

-s

--

-

--

-

-

-

--

--

-

-

-

-

-

--

-

-

--

---

-

-

-

-

-

-

Page 7: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

6

-

--

-

-

-

-

--

-

--

---

---

-

-

-

-

-

-

--

-

-

-

-

-

Page 8: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

7

-

-

-

---

-

-

-

-

-

-

-

--

-

--

-

-

-

-

--

-

--

-

-

-

-

-

__________________________________________________________________________

-

Page 9: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

8

-

-

-

--

-

-

-recepto-

-

-

renijos simptomus, o hipo-

in vivo--

-

--

-

-

-

anesthetic dissociatives

Kanabinoidai

Paranoja

Nestipriai išreikštas Nestipriai išreikštas Nestipriai išreikštasNestiprus

Priešiškumas NedidelisNesunki NeNesunki Nesunki Nesunki

Ne Ne

haliucinacijos

Page 10: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

9

-

--

--

--

--

--

-

-

-

-

-

---

-

-

--

-

--

-

--

-

-

--

-

--

-

Page 11: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

10

--

-

--

-

-

--

-

--

-

-

-

-

-

---

--

-

-

-

-

-

-

--

-

---

-

-

-

-

Page 12: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

12

-

--

-

-

-

--

-

-

-

--

--

-

-

---

-

-

-

--

-

-

--

--

-

-

--

--

-

___________________________________________________________________________-

rd

Page 13: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

13

-

--

-

-

-

-kamentai,

-

-

--

-

-

tankio cholesterolio kiekis,kiekis,

---

-

-

-

rezistentiškumas insulinui,-

--

-

Page 14: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

14

-

-

, dopami-,

-

-

--

-

-

-

American Psychiatric Associa-tion, AmericanDiabetes Association, Vaistas

Klozapinas +++ + ++++ + +++

ZiprazidonasAripiprazolisAmisulpridas*

-

-

-

-

-

-

-

-

-

__________________________________________________________________________

Page 15: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

15

--

-

-

-

-

-

-

-

-

-

-

---

--

--

--

--

-

--

--

-

-

-

Page 16: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

16

-

-

-

--

--

-

-

--

--

-

--

-

--

chomotorinis slopinimas, dezorientacija, kalbos sutrikimas

-

-

--

-

-menis, paskelbtus atlikus atsitiktine atranka paremtus kontro-

__________________________________________________________________________

-

-

Page 17: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

17

-

-

-

receptorius,

-

-

-

-

-

-

-

-

-

-

--

-

-

-

---

-

-

-

Page 18: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

18

PAN

SS b

endr

o ba

lo

Aripiprazolis,

Aripiprazolis,

Placebas

*

*** *

***

**** **

** ****

-

-

--

--

-

-,-

--

-

-

-

-

-

risperidonas, haloperidolis receptorius ir

Aripiprazolis,

Aripiprazolis,

*

*

p p

***

**

Page 19: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

20

-

-

-

-

-

-

-

-

-

---

-

-,

-

---

-

-

--

--

-

-

-

--

-

--

________________________________________________________________________

-

-

Page 20: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

21

---

sijos,

--

-

-

-

-

-

-

-

--

-

-

-

receptoriai

Cipralex

Page 21: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

22

--

--

--

-

-

-

-

-

-

-

receptorius,

-

-

-

-

--

-

-

-

--

--

-

-

________________________________________________________________________-

-

-

-

Page 22: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

23

Page 23: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

24

---

--

-

--

---

-

-

-

-

histamino recep-

-

-

-

APV-

-

-

--

--

-

-receptorius blokuojantis

-

-

-

-

Page 24: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

26

-

-

-

-

--

--

-

-

-

---

-

--

-

-

-

-

-

-

-

-

--

___________________________________________________________________________

-

Page 25: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

27

siste-neuro-

-

-

-

-

--

-

-

--

-

-

recepto-

-

-

-

---

-

-

---

--

-

LISURIDAS

---

Page 26: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

28

-

-

-

-

-

-

-

-

-

--

--

-

-

-

-

-

-

-

-

-

___________________________________________________________________________-

-

Page 27: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

30

-

--

-

-

-

-

-

-

-

-

-

-

-

--

-

-

---

-

-

-

-

Page 28: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

31

--

monotera-

--

--

-

-

-

-

-

-

__________________________________________________________________________

-

-

-

-

Politerapija

-terapija

-

Page 29: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

32

-

--

ir-

-

-

-

-

--

ir--

-

-

-

-

-

-

--

--

-

-

--

Page 30: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

33

--

-

-

--

-

-

---

-

Levodopos preparatai-

-

-

Dopamino agonistai -

-

-

-

Pramipeksolis-

-

-

-

Benzodiazepinai

Vaistai nuo epilepsijos.-

Amantadinas, -

-

-

-

--

-

--

-

--

-

-

________________________________________________________________________

-

Page 31: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

34

-

--

--

-

-

-

-

--

--

-

-

-

-

-

-

tokiems pacientams atipiniaiAPV rekomenduojami kaip pirmos ei-

-

--

-

-

---

--

-

___________________________________________________________________________-

-

Page 32: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

35

--

-

-

--

-

-

-

---

-

-

-

-

-

-

-

-

-

-

Miego higiena.

--

--

Page 33: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

36

-

--

Miego ribojimo terapija. -

---

-

-

---

--

--

-

-

--

-

SOMNOLS

-

-

--

-

-

-

-

-

--

riant hip-

___________________________________________________________________________

Page 34: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

37

-

--

-

---

-

-

--

-

-

---

-

--

-

-

--

--

-

--

--

-

prie šio ryšio sampratos

Page 35: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

38

-

--

-

-

-

--

-

-

-

-

--

-

-

-

-

-

-

-

-

--

-

-

__________________________________________________________________________-

-

-

-

Page 36: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

39

-

--

-

--

--

-

--

-

-

-tine

-

-

-

--

-

--

-

-

-

-

-

_____________________________________________________________________________

antidepresantas

Page 37: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

40

--

--

-

-

-

-

-

-

-

priešiškumas

sutrikimai

-

-tina prisiminti, kad -

-

-

-

Page 38: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

41

-

.

-

-

-

--

--

-

-

-

-

-

-

-

-

__________________________________________________________________________

-

-

-

Pav.

***

*** ***

***

***

*** *****

***

****

***

Page 39: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

42

---

--

-

-

--

--

sindromo su retencijos

-

--

-

-

-

- -

Page 40: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

43

--

-

-

-

-

---

-

-

-

-

-

-

--

-

-

-

-

-

-

-

-

Page 41: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

44

--

--

-

Neretai katatonija atsiranda kaip pereinamasis etapas

-

--

-

-

-

--

-

-

-

-

--

-

-

-

-

--

Page 42: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

45

-

--

-

-

--

--

-Psichiat-

-

-

Gydymas

---

-

-

-

--

-

-

-

-

-

-

--

______________________________________________________________________-

m

Page 43: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

46

-

-

-

-

-

-

-

-

-

-

-

-

__________________________________________________________________________

-

-

-

Page 44: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

47

-sionalo prieinamumu,

paties paciento pasirinkimu,

-

-

-

-

-

-

-

-

-

-

-

-

-

--

-

Page 45: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

48

nas sunkumas, su kuriuo susiduria specialistai dirbdami šioje

-

-

-

--

-

-

-

-

-

-

-

-

-moksta iš šios terapijos metu naudojamo psichoedukacinio

-

-

-

-

__________________________________________________________________________

-

-

,

-

Page 46: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

49

--

-

-

---

-

---

--

-

-

mis

--

--

---

-

-

-

-

-

--

-

-

-

Page 47: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

50

-

--

-

-

-

-

-

-

-

-

--

---

--

-

pri-

---

---

-

-

-

--

-

-

-

-

-

-

__________________________________________________________________________

-

Page 48: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

51

-

--

---

-

ir

-

--

-

-

-

-

-

-

-

-

-

--

--

-

-

--

-

-

-

-

Page 49: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

52

--

-

-

--

-

-

-

-

-

-

-

--

-

-

--

-

-

Page 50: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

53

-

--

--

-

-a – -

-

-

-t

-

-

-

-

-

-

-

-

--

---

--

-

-

Page 51: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

54

, tam tikros kompli-

-

-

-

-

--

-

-

-

-

--

-

-

-

-

-

--

-

-

-

-

--

--

Page 52: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

55

Gerb. daktare,

-

-

-

-

-

-

pm, t, t

Page 53: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*

56